CC-115
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- CC-115
- DrugBank Accession Number
- DB12740
- Background
CC-115 has been used in trials studying the treatment of Prostate Cancer, Neoplasm Metastasis, Ewing's Osteosarcoma, Glioblastoma Multiforme, and Chronic Lymphocytic Leukemia, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 336.359
Monoisotopic: 336.144707167 - Chemical Formula
- C16H16N8O
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyridyl-1,2,4-triazoles. These are organic compounds containing a pyridine ring attached to a 1,2,4-triazole ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyridyltriazoles
- Direct Parent
- Pyridyl-1,2,4-triazoles
- Alternative Parents
- Alpha amino acids and derivatives / Secondary alkylarylamines / Methylpyridines / Pyrazines / Imidolactams / Triazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Tertiary amines / Lactams show 4 more
- Substituents
- 1,2,4-triazole / Alpha-amino acid or derivatives / Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azole / Carbonyl group / Carboxamide group / Carboxylic acid derivative show 17 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FII75TFH5L
- CAS number
- 1228013-15-7
- InChI Key
- GMYLVKUGJMYTFB-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H16N8O/c1-3-24-13(25)7-18-15-16(24)22-12(6-17-15)10-4-5-11(21-9(10)2)14-19-8-20-23-14/h4-6,8H,3,7H2,1-2H3,(H,17,18)(H,19,20,23)
- IUPAC Name
- 1-ethyl-7-[2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl]-1H,2H,3H,4H-[1,4]diazino[2,3-b]pyrazin-2-one
- SMILES
- CCN1C(=O)CNC2=C1N=C(C=N2)C1=CC=C(N=C1C)C1=NN=CN1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 58298318
- PubChem Substance
- 347828930
- ChemSpider
- 35308328
- BindingDB
- 50093082
- ChEMBL
- CHEMBL3586573
- ZINC
- ZINC000113191351
- Wikipedia
- De_Havilland_Canada_DHC-5_Buffalo
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Castration Resistant Prostate Cancer / Prostate Cancer 1 1 Completed Treatment Chronic Lymphocytic Leukemia / Ewing's Osteosarcoma / Glioblastoma Multiforme (GBM) / Metastatic Cancer / Prostate Cancer / Squamous Cell Carcinoma of the Head and Neck (SCCHN) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0229 mg/mL ALOGPS logP 1.14 ALOGPS logP -0.36 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 8.91 Chemaxon pKa (Strongest Basic) 2.05 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 112.58 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 103.83 m3·mol-1 Chemaxon Polarizability 34.91 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-a0ca749234406172eec7 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0039000000-d53c5120d0dc04432cba Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0009000000-2a411d58122a0768674a Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4l-0089000000-5f2b81ba2cc3bf9bd3c7 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0a4l-0196000000-05c5c4bff65eb9802c7c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-1091000000-106e540bed20a4599167 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 170.62978 predictedDeepCCS 1.0 (2019) [M+H]+ 172.98778 predictedDeepCCS 1.0 (2019) [M+Na]+ 179.678 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 23:57 / Updated at June 12, 2020 16:53